Rodman & Renshaw Upgrades Abiomed to Market Perform, $10 PT

August 15, 2011 8:19 AM | 8 seconds read |
Rodman & Renshaw has upgraded Abiomed ABMD from Market Underperform to Market Perform and has established a $10 price target.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: UpgradesPrice TargetAnalyst RatingsHealth CareHealth Care EquipmentRodman & Renshaw
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!